Martin Fredriksson

BioPharmaceuticals R&D
Goeteborg, O, Sweden

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial.

Oral Relaxin Receptor Agonist AZD5462 in Participants With Chronic Heart Failure: Primary Results From the LUMINARA Trial.

Journal: Circulation

Published: August 30, 2026

Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial.

Effect of budesonide/glycopyrronium/formoterol fumarate dihydrate on cardiopulmonary outcomes in COPD: rationale and design of the THARROS trial.

Journal: ERJ open research

Published: March 10, 2025

Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).

Effect of Triple Therapy on Cardiovascular and Severe Cardiopulmonary Events in Chronic Obstructive Pulmonary Disease: A Post Hoc Analysis of a Randomized, Double-Blind, Phase 3 Clinical Trial (ETHOS).

Journal: American journal of respiratory and critical care medicine

Published: August 30, 2024

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.

Association of Cardiac Biomarkers With Major Adverse Cardiovascular Events in High-risk Patients With Diabetes: A Secondary Analysis of the DECLARE-TIMI 58 Trial.

Journal: JAMA cardiology

Published: March 01, 2023

CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research.

CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research.

Journal: BMJ (Clinical research ed.)

Published: December 23, 2022

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.

Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.

Journal: The lancet. Diabetes & endocrinology

Published: November 21, 2022

CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.

CODE-EHR best-practice framework for the use of structured electronic health-care records in clinical research.

Journal: The Lancet. Digital health

Published: July 14, 2022

CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research.

CODE-EHR best practice framework for the use of structured electronic healthcare records in clinical research.

Journal: European heart journal

Published: June 21, 2022

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial.

Journal: Diabetes care

Published: February 24, 2022

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58.

Journal: Diabetes care

Published: January 12, 2021

Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.

Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58.

Journal: Circulation

Published: August 16, 2020

Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.

Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58.

Journal: Diabetes, obesity & metabolism

Published: May 26, 2020

Showing 1-12 of 21

Last Updated: 09/26/2026